Naproxen 500 mg is NOT recommended for maintenance therapy in hidradenitis suppurativa
Naproxen has no established role in the treatment of hidradenitis suppurativa and should not be used for maintenance therapy. The comprehensive North American clinical management guidelines for HS do not include NSAIDs like naproxen in any treatment algorithm or recommendation 1.
Why Naproxen Is Not Appropriate
The FDA-approved indications for naproxen include rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout, pain management, and primary dysmenorrhea 2. Hidradenitis suppurativa is not among the approved indications, and there is no evidence supporting its use in this condition.
The Problem with NSAIDs in HS
- HS is not primarily a pain syndrome - it is a chronic inflammatory disease driven by specific immune pathways (TNF-α, IL-17, IL-1) that require targeted anti-inflammatory or immunomodulatory therapy 3
- NSAIDs do not address the underlying pathophysiology of HS, which involves follicular occlusion, bacterial colonization, and dysregulated immune responses
- Pain management in HS requires a comprehensive approach beyond simple analgesics, often necessitating multimodal strategies 4
What Should Be Used Instead for Maintenance
The evidence-based maintenance therapies for HS include:
First-Line Maintenance Options (Mild-to-Moderate Disease)
- Tetracyclines for 12-week courses or long-term maintenance when appropriate 1
- Topical clindamycin 1% solution for Hurley stage I-II disease 1
- Dapsone may be effective for a minority of patients with Hurley stage I or II disease as long-term maintenance 1
Second-Line and Severe Disease Maintenance
- Clindamycin and rifampin combination for moderate-to-severe disease 1
- Adalimumab (FDA-approved) for moderate-to-severe HS 1
- Hormonal therapies (combined oral contraceptives, spironolactone) in appropriate female patients 1
Important Caveats
The duration and frequency of antibiotic use must balance benefit against antibiotic resistance risk 1. Recurrence after cessation is frequent, which is why biologics like adalimumab have become preferred for long-term maintenance in moderate-to-severe disease 5, 4.
If your goal is pain control during HS flares, consider intralesional triamcinolone (10 mg/mL) which showed significant pain reduction within 1 day 1, or develop a comprehensive pain management strategy as part of multimodal treatment 4.